mRNA immunotherapy injected directly into tumors
Part of Cancer, Immune system & allergy clinical trials.
This trial tests a new mRNA-based treatment injected directly into solid tumors that haven't responded to standard therapy. The goal is to help your immune system recognize and attack cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Advanced or metastatic solid tumor that hasn't responded to standard treatment
- Tumor has a specific marker (EpCAM) visible on at least half of cancer cells
- At least one tumor is at least 2 cm and can be safely injected
- Good overall health (ECOG score 0–1) with life expectancy of 3+ months
- Normal blood, liver, kidney, and clotting function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a personalized mRNA vaccine, given with pembrolizumab, can help people with advanced solid tumors by training the immune system to recognize cancer. It is mainly for patients whose tumor tissue matches specific genetic and immune patterns, and who meet key safety and infection requirements.
This trial tests a personalized mRNA vaccine (InnoPCV) designed from your own tumor's genetic profile to train your immune system to fight advanced solid tumors. It is for people who have not had tumor vaccines or CAR-T therapy before and can provide a tumor sample for customized vaccine creation.
This early-stage trial tests a new mRNA-based drug designed to help your immune system fight advanced cancers that haven't responded to standard treatments. The study measures safety, tolerability, and whether it can slow or shrink your tumor.
This Phase 1/2 study tests an mRNA vaccine (mRNA-4359) either alone or combined with an immune checkpoint antibody (immunotherapy). It’s for people with advanced solid tumors to see if it can shrink tumors and how safe it is.
This trial tests an inhaled mRNA immunotherapy for people with advanced lung cancer or solid tumors that have spread to the lungs. It might help if standard treatments no longer work or aren't available.
This trial tests a personalized mRNA vaccine made from your tumor's unique markers (neoantigens) to train your immune system to fight cancer. It is for people with advanced solid tumors who have not had gene therapy and are healthy enough for the vaccine.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.